InvestorsHub Logo
Followers 145
Posts 27565
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Wednesday, 03/16/2022 9:12:44 AM

Wednesday, March 16, 2022 9:12:44 AM

Post# of 190
Kamada (KMDA) Gets a Buy Rating from H.C. Wainwright

March 16 2022 - 06:45AM


In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kamada (KMDA – Research Report), with a price target of $11.00. The company's shares closed last Tuesday at $5.60. According to TipRanks.com, Fein 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.2% and a 31.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. Kamada has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
https://www.tipranks.com/news/blurbs/kamada-kmda-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KMDA News